Clinical Features

  • Jong Kyun LeeEmail author


The diagnosis of IgG4-SC requires a high index of suspicion and understanding of clinical features is the first step of suspicion. Early recognition of IgG4-SC may lead to proper management with corticosteroids and can eventually prevent organ failure that could possibly result from a delayed diagnosis. On the contrary, a misdiagnosis of IgG4-SC as other types of sclerosing cholangitis or cholangiocarcinoma may delay the optimal treatment or result in unnecessary operation. However, the diagnosis can be challenging in some patients because of the various presentations of the disease and similar presentations of other disorders causing biliary strictures. Therefore, IgG4-SC should be considered in the differential diagnosis in all patients with unexplained biliary strictures.


  1. 1.
    Ghazale A, Chari ST, Zhang L, et al. Immunoglobulin G4-associated cholangitis: clinical profile and response to therapy. Gastroenterology. 2008;134:706–15.CrossRefPubMedGoogle Scholar
  2. 2.
    Tanaka A, Tazuma S, Okazaki K, et al. Clinical features, response to treatment, and outcomes of IgG4-related sclerosing cholangitis. Clin Gastroenterol Hepatol. 2017;15:920–6.CrossRefPubMedGoogle Scholar
  3. 3.
    Oh HC, Kim MH, Lee KT, et al. Clinical clues to suspicion of IgG4-associated sclerosing cholangitis disguised as primary sclerosing cholangitis or hilar cholangiocarcinoma. J Gastroenterol Hepatol. 2010;25:1831–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Moon SH, Kim MH, Lee JK, et al. Development of a scoring system for differentiating IgG4-related sclerosing cholangitis from primary sclerosing cholangitis. J Gastroenterol. 2017;52:483–93.CrossRefPubMedGoogle Scholar
  5. 5.
    Ohara H, Nakazawa T, Kawa S, et al. Establishment of a serum IgG4 cut-off value for the differential diagnosis of IgG4-related sclerosing cholangitis: a Japanese cohort. J Gastroenterol Hepatol. 2013;28:1247–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Ohara H, Okazaki K, Tsubouchi H, et al. Clinical diagnostic criteria of IgG4-related sclerosing cholangitis 2012. J Hepatobiliary Pancreat Sci. 2012;19:536–42.CrossRefPubMedGoogle Scholar
  7. 7.
    Nakazawa T, Ando T, Hayashi K, Naitoh I, Ohara H, Joh T. Diagnostic procedures for IgG4-related sclerosing cholangitis. J Hepatobiliary Pancreat Sci. 2011;18:127–36.CrossRefPubMedGoogle Scholar
  8. 8.
    Nishino T, Oyama H, Hashimoto E, et al. Clinicopathological differentiation between sclerosing cholangitis with autoimmune pancreatitis and primary sclerosing cholangitis. J Gastroenterol. 2007;42:550–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Takuma K, Kamisawa T, Igarashi Y. Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Curr Opin Rheumatol. 2011;23:80–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Boonstra K, Weersma RK, van Erpecum KJ, et al. Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology. 2013;58:2045–55.CrossRefPubMedGoogle Scholar
  11. 11.
    Molodecky NA, Kareemi H, Parab R, et al. Incidence of primary sclerosing cholangitis: a systematic review and meta-analysis. Hepatology. 2011;53:1590–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Tanaka A, Tazuma S, Okazaki K, et al. Nationwide survey for primary sclerosing cholangitis and IgG4-related sclerosing cholangitis in Japan. J Hepatobiliary Pancreat Sci. 2014;21:43–50.CrossRefPubMedGoogle Scholar
  13. 13.
    Hirschfield GM, Karlsen TH, Lindor KD, et al. Primary sclerosing cholangitis. Lancet. 2013;382:1587–99.CrossRefPubMedGoogle Scholar
  14. 14.
    Lindor KD, Kowdley KV, Harrison ME. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol. 2015;110:646–59.CrossRefPubMedGoogle Scholar
  15. 15.
    Nakazawa T, Naitoh I, Hayashi K, et al. Inflammatory bowel disease of primary sclerosing cholangitis: a distinct entity? World J Gastroenterol. 2014;20:3245–54.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Loftus EV Jr, Harewood GC, Loftus CG, et al. PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut. 2005;54:91–6.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Oseini AM, Chaiteerakij R, Shire AM, et al. Utility of serum immunoglobulin G4 in distinguishing immunoglobulin G4-associated cholangitis from cholangiocarcinoma. Hepatology. 2011;54:940–8.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Du S, Liu G, Cheng X, et al. Differential diagnosis of immunoglobulin G4-associated cholangitis from cholangiocarcinoma. J Clin Gastroenterol. 2016;50:501–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Tabata T, Kamisawa T, Hara S, et al. Differentiating immunoglobulin G4-related sclerosing cholangitis from hilar cholangiocarcinoma. Gut Liver. 2013;7:234–8.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media Singapore 2019

Authors and Affiliations

  1. 1.Department of Internal Medicine, Samsung Medical CenterSungkyunkwan University School of MedicineSeoulSouth Korea

Personalised recommendations